Clinical trials: Pleural Mesotheliomas
Malignant Mesothelioma
A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma
The study is designed to define the immunologic and clinical activity of Tremelimumab in patients with advanced mesothelioma.
- Trial name
- NCT01649024
- Testing
- Tremelimumab
- Where
- Italy
- Volunteers
- 29 people
- Sponsor
- Azienda Ospedaliera Universitaria Senese
Malignant Pleural Mesothelioma
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
This study will test whether giving nivolumab in combination with pemetrexed and either cisplatin or carboplatin before surgery is a safe and effective approach to treating resectable mesothelioma without delaying surgery.
- Trial name
- NCT04162015
- Testing
- Nivolumab, Pemetrexed, Cisplatin or Carboplatin
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignant Mesothelioma, Pulmonary Complications
Biomarkers to Detect Mesothelioma Early in Patients Exposed to Asbestos or Vermiculite
RATIONALE: Studying samples of body fluid and blood from patients who have been exposed to asbestos or vermiculite in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related…
- Trial name
- NCT00897247
- Testing
- microarray analysis, protein expression analysis, proteomic profiling
- Where
- United States
- Volunteers
- 494 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Advanced Malignant Pleural Mesothelioma
Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma
This is a multi-centre non-randomised open-label phase 1 trial of pembrolizumab given in combination with SBRT to part of a pleural-based lesion in patients with unresectable MPM.
- Trial name
- MESO-PRIME (NCT04166734)
- Testing
- Pembrolizumab, Stereotactic Body Radiotherapy (SBRT)
- Where
- 2 sites in United Kingdom
- Volunteers
- 5 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Malignant Pleural Mesothelioma, Advanced, Malignant Pleural Mesothelioma, Unresectable
A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma
This is a national, single arm, phase II trial in patients with diagnosis of unresectable or advanced malignant pleural mesothelioma who experienced progression after platinum-based chemotherapy.
- Trial name
- NCT03786419
- Testing
- Atezolizumab
- Where
- Mexico
- Sponsor
- Health Pharma Professional Research
Mesothelioma; Lung
Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma
This is an open-label, non-randomized, phase II, single arm, multi-center controlled clinical trial. 47 patients will be enrolled in this trial to determine the efficacy and safety of Bintrafusp alfa (M7824) in advanced malignant…
- Trial name
- BIMES (NCT05005429)
- Testing
- Bintrafusp alfa
- Where
- 15 sites in Spain
- Volunteers
- 47 people
- Sponsor
- Fundación GECP
Mesothelioma
Intrapleural Cryotherapy for Malignant Pleural Mesothelioma
Can neoadjuvant intrapleural cryotherapy be safely performed in patients with malignant pleural mesothelioma and will it trigger substantial systemic and local pro-inflammatory changes, resulting in the induction of anti-tumor…
- Trial name
- NCT02464904
- Testing
- Cryotherapy, Control
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Mayo Clinic
Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer
TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TLN-499 in combination with venetoclax in participants with relapsed/refractory solid…
- Conditions
- Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer, Malignant Pleural Mesotheliomas (Mpm), Synovial Sarcomas
- Trial name
- NCT07713732
- Testing
- TLN-499, Venetoclax
- Where
- 3 sites in Australia
- Volunteers
- 120 people
- Sponsor
- Treeline Biosciences, Inc.
Malignant Pleural Mesothelioma
A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma
To examine whether the arginine depleting drug, ADI-PEG 20, might be effective as a targeted therapy in patients with ASS-negative malignant pleural mesothelioma.
- Trial name
- ADAM (NCT01279967)
- Testing
- ADI-PEG 20
- Where
- 7 sites in United Kingdom
- Volunteers
- 70 people
- Sponsor
- Barts & The London NHS Trust
Malignant Pleural Mesothelioma
Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma
This is a single-arm, open, II phase study to evaluate the safety and efficacy of Toripalimab, pemetrexed and carboplatin in the treatment of locally advanced malignant MPM in 15 newly diagnosed patients with locally advanced…
- Trial name
- NCT04713761
- Testing
- Toripalimab
- Volunteers
- 15 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Mesothelioma
PIT: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma
The PIT (Prophylactic Irradiation of Tracts) trial will determine whether or not PIT radiotherapy is effective in preventing or delaying the onset of chest nodules in patients with Mesothelioma.
- Trial name
- PIT (NCT01604005)
- Testing
- Prophylactic Irradiation of Tracts (PIT)
- Where
- 60 sites in United Kingdom
- Volunteers
- 375 people
- Sponsor
- Brynn Chappell
Malignant Mesothelioma
Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with previously treated…
- Trial name
- NCT00509041
- Testing
- dasatinib
- Where
- 37 sites in United States
- Volunteers
- 46 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Malignant Mesothelioma
S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well everolimus works in treating patients with pleural malignant…
- Trial name
- NCT00770120
- Testing
- everolimus
- Where
- 129 sites in United States
- Volunteers
- 61 people
- Sponsor
- SWOG Cancer Research Network
Malignant Pleural Mesothelioma
Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma
This study will examine the safety and potential effectiveness of poly-ICLC directly injected into malignant pleural mesothelioma at the time of biopsy up to 21 days prior to the cancer being removed by the surgeon
- Trial name
- NCT04525859
- Testing
- Safety, Expansion Cohort
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Oncovir, Inc.
Malignant Mesothelioma
S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003723
- Testing
- gemcitabine hydrochloride
- Where
- 84 sites in United States
- Volunteers
- 57 people
- Sponsor
- SWOG Cancer Research Network
Malignant Mesothelioma
Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003263
- Testing
- recombinant interferon alfa, cisplatin, surgical procedure
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Fox Chase Cancer Center
Metastatic Pancreatic (Ductal) Adenocarcinoma, Epithelial Ovarian Cancer
CART-meso in Mesothelin Expressing Cancers
Phase I study to establish safety and feasibility of intravenously administered lentiviral transduced CART-meso cells administered with and without cyclophosphamide in a 3+3 dose escalation design in patients with metastatic…
- Conditions
- Metastatic Pancreatic (Ductal) Adenocarcinoma, Epithelial Ovarian Cancer, Malignant Epithelial Pleural Mesothelioma
- Trial name
- NCT02159716
- Testing
- CART-meso
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Pennsylvania
Small Cell Lung Cancer, Head and Neck Cancer
Comprehensive Oncogenomic Mapping and Exploration in Thoracic and Head & Neck Oncology
This is an ancillary laboratory study to collect and bank blood and tissue samples. The biospecimens collected for this study will be invaluable for future research into predictive biomarkers and genomic alterations and their…
- Conditions
- Small Cell Lung Cancer, Head and Neck Cancer, Malignant Pleural Mesothelioma
- Trial name
- COMETH (NCT07550049)
- Testing
- Blood and Tissue Collection
- Volunteers
- 110 people
- Sponsor
- University of Kansas Medical Center
Malignant Pleural Mesothelioma
Response Evaluation in Malignant Pleural Mesothelioma
Recently, a few small trials have shown promising results on value of fluoro-2-deoxy-D-glucose and positron emission tomography imaging in response assessment in Malignant Pleural Mesothelioma.
- Trial name
- NCT00969098
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Istituto Clinico Humanitas
Malignant Pleural Mesothelioma, Chemotherapy Effect
Effect of HITHOC After Pleurectomy Decortication for Treatment of Malignant Pleural Mesothelioma
Malignant pleural mesothelioma (MPM) is an aggressive malignancy of the pleural lining with exceptionally poor survival. Median survival from diagnosis is less than 12 months (1).
- Trial name
- NCT05508555
- Testing
- hyperthermic intrathoracic chemotherapy
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Ain Shams University